124 related articles for article (PubMed ID: 37633047)
21. Racial differences in RAD51 expression are regulated by miRNA-214-5P and its inhibition synergizes with olaparib in triple-negative breast cancer.
Mani C; Acharya G; Saamarthy K; Ochola D; Mereddy S; Pruitt K; Manne U; Palle K
Breast Cancer Res; 2023 Apr; 25(1):44. PubMed ID: 37081516
[TBL] [Abstract][Full Text] [Related]
22. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
[TBL] [Abstract][Full Text] [Related]
23. Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells.
Malka MM; Eberle J; Niedermayer K; Zlotos DP; Wiesmüller L
Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356606
[TBL] [Abstract][Full Text] [Related]
24. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
25. Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.
Kalimutho M; Bain AL; Mukherjee B; Nag P; Nanayakkara DM; Harten SK; Harris JL; Subramanian GN; Sinha D; Shirasawa S; Srihari S; Burma S; Khanna KK
Mol Oncol; 2017 May; 11(5):470-490. PubMed ID: 28173629
[TBL] [Abstract][Full Text] [Related]
26. LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer.
Dey G; Bharti R; Braley C; Alluri R; Esakov E; Crean-Tate K; McCrae K; Joehlin-Price A; Rose PG; Lathia J; Gong Z; Reizes O
J Ovarian Res; 2023 Jun; 16(1):122. PubMed ID: 37370140
[TBL] [Abstract][Full Text] [Related]
27. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
Pharm Res; 2018 Sep; 35(11):218. PubMed ID: 30255456
[TBL] [Abstract][Full Text] [Related]
28. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition.
Sakogawa K; Aoki Y; Misumi K; Hamai Y; Emi M; Hihara J; Shi L; Kono K; Horikoshi Y; Sun J; Ikura T; Okada M; Tashiro S
Cancer Sci; 2013 Dec; 104(12):1593-9. PubMed ID: 24033642
[TBL] [Abstract][Full Text] [Related]
29. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
[TBL] [Abstract][Full Text] [Related]
30. Functional inhibition of RECQL5 helicase elicits non-homologous end joining response and sensitivity of breast cancers to PARP inhibitor.
Philip KT; Dutta K; Chakraborty S; Patro BS
Int J Biochem Cell Biol; 2023 Aug; 161():106443. PubMed ID: 37392863
[TBL] [Abstract][Full Text] [Related]
31. Rad18 and Rnf8 facilitate homologous recombination by two distinct mechanisms, promoting Rad51 focus formation and suppressing the toxic effect of nonhomologous end joining.
Kobayashi S; Kasaishi Y; Nakada S; Takagi T; Era S; Motegi A; Chiu RK; Takeda S; Hirota K
Oncogene; 2015 Aug; 34(33):4403-11. PubMed ID: 25417706
[TBL] [Abstract][Full Text] [Related]
32. β1-Integrin Impacts Rad51 Stability and DNA Double-Strand Break Repair by Homologous Recombination.
Ahmed KM; Pandita RK; Singh DK; Hunt CR; Pandita TK
Mol Cell Biol; 2018 May; 38(9):. PubMed ID: 29463647
[TBL] [Abstract][Full Text] [Related]
33. The cancer-testis gene,
Gu Y; Wang C; Zhu R; Yang J; Yuan W; Zhu Y; Zhou Y; Qin N; Shen H; Ma H; Wang H; Liu X; Hu Z
Cancer Biol Med; 2021 Feb; 18(1):74-87. PubMed ID: 33628586
[TBL] [Abstract][Full Text] [Related]
34. Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation.
Gasparini P; Lovat F; Fassan M; Casadei L; Cascione L; Jacob NK; Carasi S; Palmieri D; Costinean S; Shapiro CL; Huebner K; Croce CM
Proc Natl Acad Sci U S A; 2014 Mar; 111(12):4536-41. PubMed ID: 24616504
[TBL] [Abstract][Full Text] [Related]
35. PTEN Loss Enhances Error-Prone DSB Processing and Tumor Cell Radiosensitivity by Suppressing RAD51 Expression and Homologous Recombination.
Pei X; Mladenov E; Soni A; Li F; Stuschke M; Iliakis G
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361678
[TBL] [Abstract][Full Text] [Related]
36. Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs.
Quiros S; Roos WP; Kaina B
PLoS One; 2011; 6(11):e27183. PubMed ID: 22073281
[TBL] [Abstract][Full Text] [Related]
37. Fisetin induces DNA double-strand break and interferes with the repair of radiation-induced damage to radiosensitize triple negative breast cancer cells.
Khozooei S; Lettau K; Barletta F; Jost T; Rebholz S; Veerappan S; Franz-Wachtel M; Macek B; Iliakis G; Distel LV; Zips D; Toulany M
J Exp Clin Cancer Res; 2022 Aug; 41(1):256. PubMed ID: 35989353
[TBL] [Abstract][Full Text] [Related]
38. Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition.
Pai Bellare G; Saha B; Patro BS
Br J Cancer; 2021 Mar; 124(7):1260-1274. PubMed ID: 33473172
[TBL] [Abstract][Full Text] [Related]
39. The VEGF receptor neuropilin 2 promotes homologous recombination by stimulating YAP/TAZ-mediated Rad51 expression.
Elaimy AL; Amante JJ; Zhu LJ; Wang M; Walmsley CS; FitzGerald TJ; Goel HL; Mercurio AM
Proc Natl Acad Sci U S A; 2019 Jul; 116(28):14174-14180. PubMed ID: 31235595
[TBL] [Abstract][Full Text] [Related]
40. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
Ha K; Fiskus W; Choi DS; Bhaskara S; Cerchietti L; Devaraj SG; Shah B; Sharma S; Chang JC; Melnick AM; Hiebert S; Bhalla KN
Oncotarget; 2014 Jul; 5(14):5637-50. PubMed ID: 25026298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
